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◎症 例
A case with persistent asthma symptoms despite
fluticasone treatment in which concomitant treat-
ment with montelukast and perilla seed oil-rich sup-
plementation significantly improved asthma control
Shingo Takata１), Kozo Ashida１), Yasuhiro Hosaki１),
Masanori Hamada２), Naofumi Iwagaki１), Hiroshi Kikuchi１)
and Fumihiro Mitsunobu１)
１)Division of Medicine, ２)Division of Rehabilitation, Misasa Medical Center,
Okayama University Hospital of Medicine and Dentistry
Abstract：A 25-year-old woman had the chief complaint of recurrent episodes of dyspnea
and wheeze. Asthma had been diagnosed at infant years and sometimes experienced
asthma attacks. She graduated senior high school and entered technical school in Tokyo.
She received fluticasone (400μg daily) but exacerbation continued after she became an of-
fice clerk. She returned Kurashiki in October 2001 but had wheeze and asthma exacerbations.
She was admitted to our hospital for evaluation and treatment of bronchial asthma on
August 2, 2002. After admission, her symptoms subsided within some days. She was
treated with montelukast and perilla seed oil-rich supplementation . The number of
eosinophils decreased, decrease was observed in leukotriene (LT) B4 generation and in
LTC4 generation, and pulmonary function improved following montelukast and perilla seed
oil-rich supplementation for 4 weeks. The patient had no exacerbation under treatment and
was discharged from the hospital on September 2, 2002. For some patients with persistent
asthma, inhaled corticosteroids may fail to achieve adequate control possibly because
corticosteroids do not completely inhibit the synthesis and release of cysteinyl leukotrienes
(cysLTs) in the lung. Montelukast blocks the interaction of cysLTs with their receptor and
resulting downstream events and perilla seed oil-rich diet suppresses LT generation. Com-
bination therapy with montelukast and perilla seed oil-rich diet is more effective than
montelukast or perilla seed oil-rich diet alone because of additive effects of montelukast
with perilla seed oil-rich diet. We suggest that montelukast and perilla seed oil-rich supple-
mentation are effective options when bronchial asthma patients receive inhaled
corticosteroid but exacerbation continues.
Key words：montelukast, bronchial asthma, leukotriene C4,
perilla seed oil-rich supplementation, fluticasone
Introduction
Asthma is a chronic inflammatory disease
characterized by the presence of inflammatory
cells such as T lymphocytes, mast cells, and
eosinophils in the airways１). Characteristic fea-
tures of asthma include mucus hypersecretion,
airways hyperreactivity, and changes in airway
morphology (for example , increased airway
smooth muscle mass, subepithelial fibrosis,
edema , eptithelial cell damage) . Cysteinyl
leukotrienes (cysLTs) such as leukotriene (LT)
C４, LTD４, and LTE４ are produced from a vari-
ety of inflammatory cells including mast cells,
basophils, eosinophils and macrophages, all of
which may contribute to the pathogenesis of
asthma２-５). Antileukotriene drugs are the effec-
tive therapy for asthma currently available and
have been used in such patients with few side
effects１,６). Previously, we have reported the in-
hibitory effect on the generation of leukotrienes
by peripheral leucocytes with a diet containing
perilla seed oil, a vegetable oil rich in α-linolenic
acid (α-LNA)７). However, it is still unclear
whether concomitant treatment with montelukast
and dietary supplementation of perilla seed oil
influences on the pathophysiology of bronchial
asthma or not. We report a case with mild air-
way obstruction and persistent asthma symp-
toms despite fluticasone treatment in which con-
comitant treatment with montelukast and perilla
seed oil-rich supplementation significantly im-
proved asthma control.
Case Report
A 25-year-old woman had the chief complaint
of recurrent episodes of dyspnea and wheeze.
She had a history of pneumonia in childhood
and allergic rhinitis. She was an office clerk. She
drank alcohol socially and did not use tobacco.
Her mother had hypertension and migraine. Her
father's brother had bronchial asthma . Her
mother's brother had lung cancer. Two broth-
ers had atopic dermatitis.
Asthma had been diagnosed at infant years
and she was often admitted to hospitals until
she graduated elementary school. She some-
times experienced asthma attacks in junior and
senior high school. She graduated senior high
school and entered technical school in Tokyo.
She received fluticasone (400μg daily) but ex-
acerbation continued after she became an office
clerk. She returned Kurashiki in October 2001
but had wheeze and asthma exacerbations. She
was admitted to our hospital for evaluation and
treatment of bronchial asthma on August 2, 2002.
Her height was 161.2㎝ and body weight was
62.7㎏；her body temperature was 36.8℃,
blood pressure 90／60㎜Hg and heart rate 68／
minute. There were no rales in the lung field.
Heart sounds were normal. The laboratory find-
ings on admission are shown in Table１. Leu-
kocyte count was 4600／ μ  with 37％
polymorphonuclear cells, 13％ eosinophils (an
absolute count of 598／μ), 49％ lymphocytes
and １％ monocytes. Immunoglobulin E was
elevated 1253 IU／ml. Radioallergosorbent tests
for Dermatophagoides pteronyssinus, Dermato-
phagoides farinae, house dust, cedar, cat and
dog were positive.
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After admission, her symptoms subsided within
some days(Fig.１).Fluticasone(400μg daily) was
stopped and budesonide(400μg daily) was given.
She was treated with montelukast and perilla
seed oil-rich supplementation. The number of
eosinophils decreased following montelukast and
perilla seed oil-rich supplementation for 4 weeks
(598 to 405／μ) (Fig.２). Decrease was ob-
served in LTB4 generation (94.2 to 60.0ng／
５×10６ cells) (Fig.３) and in LTC4 generation
by leucocytes (76.5 to 49.4ng／５×10６cells)
(Fig.４) for 4 weeks. Pulmonary function tests
were performed using a Chestac 33 (Chest Co.,
Tokyo, Japan) linked to a computer. Vital ca-
pacity (VC) , forced vital capacity (FVC) ,
forced expiratory volume in one second (FEV１),
forced expiratory flow after 25％ of expired FVC
(FEF25), forced expiratory flow after 50％ of ex-
pired FVC (FEF50), forced expiratory flow after
75％ of expired FVC (FEF75), mean expiratory
flow during the middle half of the FVC (FEF25-75)
and peak expiratory flow (PEF) improved at 4
weeks after receiving montelukast and dietary
supplementation with perilla seed oil (Table２).
Morning PEF and evening PEF increased 60.0
／min for 4 weeks (Fig.１). The patient had
no exacerbation under treatment and was dis-
charged from the hospital on September 2, 2002.
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Table 1  Laboratory data on admission 
                                 
CBC                       Allergic examination   
WBC   4600/            IgE(RIST)     1253 IU/ml 
Stab  0.0%                  
Seg    37.0%             IgE(RAST)                       
  Lymph 49.0%              Dermatophagoides pteronyssinus 
  Mono   1.0%              Dermatophagoides farinae        
  Eos    13.0%              House dust 1                    
  Baso    0.0%              House dust 2                    
RBC  434104/           Aspergillus                     
Hgb      13.0 g/           Candida                        
Hct       38.1%             Cedar                          
PLT  23.1104/           Cat (dandruff)                  
                             Rice                            
Chemistry                   Cockroach                      
T.P.        7.3 g/           Dog (dandruff)                
Alb        4.0 g/           Serology 
BUN      7.3 /          IgG      1301 /
Cr         0.7 /          IgA       256 /
UA     5.2 /          IgM      134 /
AST       18 IU/ml          HBs Ag          (-) 
ALT       25 IU/ml          Anti-HCV Ab     (-) 
ChE    11.49 IU/ml 
-GTP     9 IU/ml          Hormone study 
AMY      51 IU/ml          Cortisol   23.4 g/
T.Chol    158/
TG        85/
HDL       64/
Fig.1 Clinical course
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Fluticasone propionate 400㱘g
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Fig.2 Changes in the number of eosinophils. 
The number of eosinophils decreased for 4 weeks.
㪇
㪈㪇㪇
㪉㪇㪇
㪊㪇㪇
㪋㪇㪇
㪌㪇㪇
㪍㪇㪇
㪙㪼㪽㫆㫉㪼 㪋㩷㫎㪼㪼㫂㫊
㪜㫆
㫊㫀
㫅㫆
㫇㪿
㫀㫃
㩿㪆
P㪣
㪀
Asthma is a chronic inflammatory disorder of
the airways in which many cells and cellular ele-
ments play a role. The chronic inflammation
causes an associated increase in airway hyper-
responsiveness that leads to recurrent episodes
of wheezing, breathlessness, chest tightness,
and coughing, particularly at night or in the
early morning. These episodes are usually asso-
ciated with widespread but variable airflow ob-
struction that is often reversible either spontane-
ously or with treatment１). Inhaled corticosteroids
(ICS) affect a variety of inflammatory pathways
in asthma and represent a gold standard in anti-
inflammatory treatment１). However, for some
patients with persistent asthma, ICS may fail to
achieve adequate control possibly because
corticosteroids do not completely inhibit the syn-
thesis and release of cysLTs in the lung８). The
cysLTs induce many of the pathophysiological
changes present in the lungs of patients with
asthma, including airflow obstruction, mucus
secretion, reduced mucociliary clearance, and
inflammatory cell infiltration. Montelukast , a
cysteinyl leukotriene type 1 (CysLT1) receptor
antagonist, has been found to reduce airway
eosinophilic inflammation in patients with
chronic asthma９-11) . Many inflammatory proc-
esses escape modulation by glucocorticosteroids,
whereas glucocorticosteroids have paradoxical
effects on other processes . Notable among
these is the leukotriene pathway. Several clini-
cal trials indicate an additive effect of
glucocorticosteroids and montelukast on pulmo-
nary function, even in patients receiving high-
dose inhaled or oral glucocorticosteroids, sug-
gesting that LT synthesis in asthmatic persons
is resistant to glucocorticosteroids suppression８).
For patients with persistent asthma symptoms
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Fig.3  Changes in LTB4 generation by leucocytes
LTB4 generation decreased after montelukast and perilla seed 
oil-rich supplementation for 2 and 4 weeks.
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Fig.4  Changes in LTC4 generation by leucocytes
LTC4 generation decreased after montelukast and perilla seed 
oil-rich supplementation for 2 and 4 weeks.
LTC4:leukotriene C4
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Table 2  Changes of ventilatory parameters by montelukast and dietary 
supplementation 
 Montelukast and dietary supplementation 
 Before 4weeks 
VC() 3.32 3.49 
FVC() 3.32 3.40 
FEV1() 2.44 2.93 
FEF75(/sec) 3.71 6.02 
FEF50(/sec) 2.38 4.09 
FEF25(/sec) 0.53 1.41 
FEF25-75(/sec) 2.29 3.98 
%RV(%) 72.3 41.9 
%FRC(%) 98.6 88.7 
%PEF(%) 57.3 93.2 
%DLco(%) 85.3 94.0 
                                 
VC:vital capacity, FVC:forced vital capacity 
FEV1: forced expiratory volume in one second 
FEF75: forced expiratory flow after 75% of expired FVC 
FEF50: forced expiratory flow after 50% of expired FVC 
FEF25: forced expiratory flow after 25% of expired FVC 
FEF25-75: mean expiratory flow during the middle half of FVC 
RV: residual volume, FRC: functional residual capacity 
PEF: peak expiratory flow, DLco: diffusing capacity for carbon monoxide 
Discussion
despite ICS treatment, concomitant treatment
with montelukast significantly improves asthma
control10).
We have reported the inhibitory effect on the
generation of LTs by peripheral leucocytes with
a diet containing perilla seed oil, a vegetable oil
rich in α-linolenic acid (α-LNA)７). Polyunsatu-
rated fatty acids (PUFAs) of the n-3 fatty acids
[EPA and docosahexaenoic acid (DHA)] sup-
press the production of ‘4-series’LTs by com-
petitive antagonistic metabolism, which occurs
at the level of LT hydrolase through the 5-
lipoxygenase pathway. Therefore, PUFAs may
potentially alter LT generation by leucocytes12).
Several reports have shown the beneficial effects
of EPA or fish oil on bronchial asthma13-17).
However, little is known about the effects of
adding montelukast combined with dietary sup-
plementation of perilla seed oil on asthma.
This case had mild airway obstruction and
persistent asthma symptoms despite ICS treat-
ment in which the addition of montelukast and
perilla seed oil-rich supplementation produced
substantial improvements in asthma control.
Reiss reported that montelukast significantly im-
proved airway obstruction, as shown by an in-
crease in FEV１ of 13.1％, in morning PEF of
24.0／min, and in evening PEF of 15.9
／min in asthmatic patients18). Okamoto et al.
reported that perilla seed oil-rich supplementa-
tion was effective in the treatment of asthma, as
shown by an increase in FEV１ of 11.7％ and in
morning PEF of 40.7／min19). In this case
montelukast and perilla seed oil-rich supplemen-
tation significantly improved pulmonary function,
as shown by an increase in FEV１ of 20.1％, in
morning PEF of 60.0／min, and in evening
PEF of 60.0／min in asthmatic patients.
Montelukast blocks the interaction of cysLTs
with their receptor and resulting downstream
events18) and perilla seed oil-rich diet suppresses
LT generation19) . Combination therapy with
montelukast and perilla seed oil-rich diet is
more effective than montelukast or perilla seed
oil-rich diet alone because of additive effects of
montelukast with perilla seed oil-rich diet. We
suggest that montelukast and perilla seed oil-
rich supplementation are effective options when
bronchial asthma patients receive ICS but exac-
erbation continues.
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Fluticasone 投与にもかかわらず症状が軽快ぜす
n-3系不飽和脂肪酸強化食による食事療法及びモ
ンテルカストが著効した気管支喘息の１例
高田真吾１), 芦田耕三１), 保泰弘１),
濱田全紀２), 岩垣尚史１), 菊池 宏１),
光延文裕１)
岡山大学病院三朝医療センター内科１)
同 三朝医療センターリハビリテーション科２)
症例は25歳女性, 主訴は呼吸困難, 喘鳴｡ 乳児
期気管支喘息発症し, 以後も喘息発作を認めた｡
高校卒業後上京し, 就職後fluticasone propionate
400μg投与にもかかわらず, 喘息発作が続いて
いた｡ 2001年10月倉敷に帰郷後も喘鳴, 発作を認
め, 2002年８月２日精査加療目的で当院入院となっ
た｡ 入院後速やかに喘鳴は消退した｡ エゴマ油食,
montelukast sodium投与開始し, 血中好酸球, 白
血球leukotriene B4, leukotriene C4低下, 呼吸
機能改善を認めた｡ その後喘息発作, 喘鳴などは
再発せず, ９月２日退院となった｡ 吸入ステロイ
ド薬単独治療では症状を十分に管理できない患者
が存在する｡ その原因としてステロイド薬はロイ
コトリエンの産生を完全に抑制できないことが挙
げられる｡ ロイコトリエンによる気道炎症は,
montelukastをはじめとするロイコトリエン受容
体拮抗薬によって特異的に抑制され, エゴマ油食
もロイコトリエン産生を抑制すると報告されてい
る｡ 本症例ではmontelukastおよびエゴマ油食の
相加効果により, 各々の単独投与より良好な結果
が得られた｡ 従って吸入ステロイドで喘息コント
ロール不良な症例に対してmontelukastおよびエ
ゴマ油食を併用することが望まれる｡
索引用語：モンテルカスト, 気管支喘息, ロイコ
トリエンC4, エゴマ油食, フルチカゾン
